Physician profile
Loree A Easley
NPI 1417108259
$186,557.21
in general payments reported to CMS, 2019-2025
33 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $22K · 2023: $40K · 2024: $68K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Food and Beverage: $17K · Consulting Fee: $14K · Travel and Lodging: $11K · Education: $438 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108,282.70 |
| Food and Beverage | $16,783.46 |
| Consulting Fee | $13,817.50 |
| Travel and Lodging | $10,962.51 |
| Education | $438.21 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $43,779.94 | 2021-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $34,327.61 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $27,317.07 | 2021-2025 | |
| Galderma Laboratories, L.P. | $26,158.38 | 2021-2025 | Aklief, Twyneo, Epsolay |
| Janssen Scientific Affairs, LLC | $18,710.25 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $11,400.03 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $6,628.72 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $5,284.72 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $4,106.51 | 2021-2025 | |
| Leo Pharma INC. | $2,125.63 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $1,099.18 | 2021-2025 | Opzelura |
| Pfizer INC. | $751.91 | 2021-2024 | |
| Medimetriks Pharmaceuticals, INC. | $608.03 | 2022-2023 | Neo-Synalar |
| Genzyme Corporation | $601.72 | 2021-2025 | |
| Journey Medical Corporation | $516.90 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $514.04 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $501.37 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $496.91 | 2021-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $429.51 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Dermavant Sciences, INC. | $285.99 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.24 | 2023-2025 | Spevigo, Cyltezo |
| Almirall LLC | $160.13 | 2022-2024 | Klisyri, Seysara |
| Vyne Pharmaceuticals INC. | $144.96 | 2021 | |
| Organon LLC | $105.28 | 2025 | Vtama |
| Organogenesis INC. | $94.45 | 2022-2025 | Novachor, Affinity |
| Mayne Pharma Commercial LLC | $61.20 | 2022-2023 | |
| Botanix Sb INC | $53.18 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $30.10 | 2021 | |
| Sandoz INC. | $23.47 | 2025 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $20.48 | 2025 | Acthar |
| Nabriva Therapeutics, Plc | $15.04 | 2022 | |
| Biofrontera INC. | $10.26 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loree Easley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.